查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1555040

老年癡呆症治療藥市場:各類藥物，各流通管道，各地區，機會，預測，2017年～2031年

Alzheimer's Therapeutics Market Assessment, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 248 Pages | 商品交期: 3-5個工作天內

價格

2024-2031年預測期間，全球阿茲海默症藥物市場規模將以11.90%的複合年增長率擴大，從2023年的51.6億美元增長到2031年的126.8億美元。由於該疾病病例數量不斷增加、政府措施不斷增加以及研發投資不斷增加，阿茲海默症治療市場預計將在預測期內快速成長。

在多種因素和時事的推動下，阿茲海默症藥物市場正在動態成長。醫療保健和藥品的改進，加上阿茲海默症 (AD) 負擔的不斷增加，加速了對有效治療方案的需求。世界人口老化和疾病意識增強等人口變化也是推動成長的關鍵因素。

阿茲海默症的發生率在過去幾十年中一直呈上升趨勢，預計未來還會繼續增加。高收入國家預期壽命的延長使許多老齡化人口面臨阿茲海默症的風險。盛行率的不斷上升支撐著對有效治療和全球衛生措施不斷增長的需求，以抵消這些健康差異。隨著阿茲海默症病例持續增加，對目前和新治療方法的需求也在增加。這一增長也為老年人口增加和醫療保健系統發展的國家的阿茲海默症藥物市場提供了成長潛力。阿茲海默症目前在全球公共衛生議題中排名第七。根據阿茲海默症協會發布的數據，到 2023 年，大約 8,700 萬人將患有早期阿茲海默症，3,200 萬人將患有輕度至重度阿茲海默症。隨著阿茲海默症病例在可預見的未來繼續以同樣的速度增加，阿茲海默症藥物的市場機會預計將擴大。

本報告提供全球老年癡呆症治療藥市場相關調查，提供市場概要，以及各類藥物，各流通管道，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 全球阿茲海默症治療藥市場預測，2017年～2031年

  • 市場規模的分析與預測
  • 市場佔有率分析與預測
  • 市場地圖分析，2023年
    • 各類藥物
    • 各流通管道
    • 各地區

第5章 北美的阿茲海默症治療藥市場預測，2017年～2031年

第6章 歐洲的阿茲海默症治療藥市場預測，2017年～2031年

第7章 亞太地區的阿茲海默症治療藥市場預測，2017年～2031年

第8章 南美的阿茲海默症治療藥市場預測，2017年～2031年

第9章 中東·非洲的阿茲海默症治療藥市場預測，2017年～2031年

第10章 價值鏈分析

第11章 波特的五力分析

第12章 大環境分析

第13章 價格分析

第14章 市場動態

第15章 市場趨勢與發展

第16章 法規結構和革新

第17章 專利的形勢

第18章 案例研究

第19章 競爭情形

  • 市場領導前五名的競爭矩陣
  • 參與企業前五名的SWOT分析
  • 市場前10位主要參與者的情況
    • AbbVie Inc.
    • Novartis AG
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Janssen Pharmaceuticals, Inc.
    • F. Hoffmann La Roche Ltd.
    • Daiichi Sankyo Company, Limited
    • Bristol-Myers Squibb Company
    • Teva Pharmaceuticals Ltd.
    • Aurobindo Pharma Ltd.
    • Biogen, Inc.

第20章 策略性建議

第21章 諮詢方式和免責聲明

Product Code: MX11877

Global Alzheimer's therapeutics market is projected to witness a CAGR of 11.90% during the forecast period 2024-2031, growing from USD 5.16 billion in 2023 to USD 12.68 billion in 2031. With growing cases of diseases, increasing government initiatives, and rising research and development investments, the Alzheimer's therapeutics market is forecast to see rapid growth during the forecast period.

The Alzheimer's therapeutics market is growing dynamically, impelled by several factors and current events. Improving healthcare and pharmaceuticals, allied with the ever-increasing burden of Alzheimer's disease (AD), accelerates the demand for effective treatment options. The demographic change of aging populations around the world, along with increased awareness of the disease, are other major factors driving the growth. Recent innovations and investments in new drug formulations and diagnostic tools are other principal reasons for the growth. For instance, in July 2024, Eli Lilly and Company received approval from the U.S. Food and Drug Administration for Kinsula (donanemab-azbt) designed for treating Early Symptomatic Alzheimer's Disease. This adds to the previously approved treatments: Leqembi (lecanemab) approved in 2023 and Aduhelm (aducanumab) which was approved in 2021. These recent FDA approvals prove that the regulatory agencies are involved in advancing the options for Alzheimer's treatment. Approval of these new drugs marks increased interest in addressing AD and is fueling the expansion of the Alzheimer's therapeutics market. Apart from the advantages that new therapies could bring to patients, once they hit the market, they increase investment and competition in the field of Alzheimer's therapeutics, further driving growth and innovation.

Rising Prevalence of Aging Population and Alzheimer's Disease

Alzheimer's disease has been increasing in magnitude over the last decades and continues to be projected to increase in the future. Higher life expectancy in high-income countries exposes more of the aging population to the risk of developing AD. The growing prevalence underpins rising demand for effective treatments and global health initiatives to offset these health disparities. As the cases of AD continue to increase, so will the need for current and new treatments. This increase also brings the potential for Alzheimer's therapeutics market growth in countries with growing elderly populations and growing healthcare systems. AD currently ranks as the seventh leading cause of public health problems in the world. As per the data published by the Alzheimer's Association, in 2023, there were around 87 million people suffering from Alzheimer's at an early stage of the disease, while 32 million have a mild to severe form of this illness. As the cases of AD are going to increase at the same pace in the foreseeable future, it will lead to a greater market opportunity for Alzheimer's therapeutics.

Rising Investments in Research and Development Drive Market Growth

Investments in Alzheimer's therapeutics have been growing worldwide through multiple initiatives and funding strategies placed by stakeholders to fast-track the sector. This ranges from increasing funds for R&D to regulatory frameworks that ease business operations and production-based initiative investments to build resilience in manufacturing and supply chains, among others. For instance, this rise in investment in research and development enables the identification of new treatments against Alzheimer's. For example, in July 2024, Asceneuron SA, a Merck KGaA spin-out, headquartered in Switzerland, raised USD 100 million to develop a drug for treating AD. The company is working on developing therapies directed against proteins involved in the progression of Alzheimer's disease and other neurodegenerative disorders. Moreover, in May 2024, Coya Therapeutics, Inc., a clinical trial phase company, was granted a USD 5 million strategic investment by the Alzheimer's Drug Discovery Foundation to fund its research. The company aims to develop biologics for the treatment of AD. Increasing investments not only pave the way for innovations but also increase the pipeline of drugs with potential treatments for Alzheimer's disease, thus boosting the overall Alzheimer's therapeutics market.

Dominance of Cholinesterase Inhibitors in the Alzheimer's Therapeutics Market

Cholinesterase inhibitor drugs have been proven to treat cognitive symptoms, as well as extended clinical validation and regulatory approval across the board. Donepezil, rivastigmine, and galantamine are drugs that increase acetylcholine levels in the brain, therefore enhancing memory and improving general cognitive function in patients suffering from Alzheimer's. Their long-standing presence and vast clinical experience add to their strong level of trust with healthcare providers and patients. Besides, such drugs are included in the standard treatment schedules for Alzheimer's, thereby further cementing their place in the Alzheimer's therapeutics market. The cost-effectiveness of these drugs, as compared to new and expensive treatments, and the continuous research being done for their enhancement in effectiveness and reduction of side effects will continue to give them a clean sweep in the Alzheimer's therapeutics market. For instance, in July 2024, the FDA approved ALPHA-1062, a new-generation Acetylcholinesterase Inhibitor-based treatment. This drug is designed to address cognitive decline and other mild-to-moderate symptoms of Alzheimer's disease.

North America Dominates Alzheimer's Therapeutics Market Share

North America is expected to dominate the Alzheimer's therapeutics market. The rising geriatric population, coupled with high drug accessibility and significant government investments to improve the quality of diagnosis and care, are the major factors contributing to market growth. For example, nearly 6.9 million American people aged 65 years and older currently live with Alzheimer's disease, and this figure is expected to grow to 13.8 million by 2060. The other thing is that North America is advanced in R&D and is one of the leaders in providing outstanding progress in the treatment of Alzheimer's disease. Apart from these, other reasons include better health care policies, better economic conditions, and innumerable strategic partnerships, such as Eisai Co., Ltd., in March 2024, announced an investment of up to USD 15 million in C2N Diagnostics LLC to simplify early diagnosis of Alzheimer's disease to provide due service to its patients.

Future Market Scenario (2024-2031F)

Advances in diagnostic technologies are enabling the scope for earlier and more accurate diagnosis of Alzheimer's disease. Better tools for diagnosing the disease at its early stage can enhance the likelihood of effective treatment options and maximize the effectiveness of treatment. These improvements in diagnosis can increase the demand for Alzheimer's therapeutics, hence impacting the Alzheimer's therapeutics market. For example, researchers at the University of Cambridge have developed cutting-edge artificial intelligence models that not only predict Alzheimer's disease but are more accurate than the current clinical tests.

The rising cases of Alzheimer's, particularly among the elderly population, are expected to increase the demand for therapeutic solutions. According to scientific estimates, cases of Alzheimer's will surge to approximately 152.8 million by 2050 from the 51.62 million reported in 2019. Such a rise in cases highlights the need for more effective and advanced treatments in the future. Also, ongoing research into neurological diseases will further set the trends for the future.

Key Players Landscape and Outlook

Leading market players in the global Alzheimer's therapeutics market focus on R&D investments and new product launches to cater to the growing demand for effective treatments. The Alzheimer's therapeutics market landscape is highly competitive, featuring several players at the local and global levels. Companies are adopting different strategies like fastening regulatory approvals and improving supply chain and production.

In March 2024, Bristol-Myers Squibb Company completed the acquisition of Karuna Therapeutics, Inc. for USD 14 million. This acquisition will expand the neuroscience portfolio of Bristol-Myers Squibb Company. Karuna Therapeutic is developing KarXT, which is targeted at treating psychosis, a major therapeutic focus for Alzheimer's disease. This acquisition can position BMS as a leader in Alzheimer's therapeutics.

AbbVie Inc. completed the acquisition of Cerevel Therapeutics in December 2023 in a deal worth USD 8.7 billion. This transaction is intended to increase AbbVie's neuroscience pipeline by adding clinical-stage therapies developed by Cerevel to AbbVie's neurosciences products that are currently in development or have been launched. With an innovative approach to neuroscience, the company will be able to expand its novel therapies into more neurological conditions in patients through AbbVie's deep experience in developing and commercializing global medicines.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Alzheimer's Therapeutics Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Drug Class
      • 4.2.1.1. Cholinesterase Inhibitors
      • 4.2.1.2. NMDA Receptor Antagonist
      • 4.2.1.3. Manufactured Combination
      • 4.2.1.4. Others
    • 4.2.2. By Distribution Channel
      • 4.2.2.1. Hospital Pharmacies
      • 4.2.2.2. Retail Pharmacies
      • 4.2.2.3. E-Pharmacies
    • 4.2.3. By Region
      • 4.2.3.1. North America
      • 4.2.3.2. Europe
      • 4.2.3.3. Asia-Pacific
      • 4.2.3.4. South America
      • 4.2.3.5. Middle East and Africa
    • 4.2.4. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Drug Class
    • 4.3.2. By Distribution Channels
    • 4.3.3. By Region

5. North America Alzheimer's Therapeutics Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. Cholinesterase Inhibitors
      • 5.2.1.2. NMDA Receptor Antagonist
      • 5.2.1.3. Manufactured Combination
      • 5.2.1.4. Others
    • 5.2.2. By Distribution Channels
      • 5.2.2.1. Hospital Pharmacies
      • 5.2.2.2. Retail Pharmacies
      • 5.2.2.3. E-Pharmacies
    • 5.2.3. By Country Share
      • 5.2.3.1. United States
      • 5.2.3.2. Canada
      • 5.2.3.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Alzheimer's Therapeutics Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Drug Class
          • 5.3.1.2.1.1. Cholinesterase Inhibitors
          • 5.3.1.2.1.2. NMDA Receptor Antagonist
          • 5.3.1.2.1.3. Manufactured Combination
          • 5.3.1.2.1.4. Others
        • 5.3.1.2.2. By Distribution Channels
          • 5.3.1.2.2.1. Hospital Pharmacies
          • 5.3.1.2.2.2. Retail Pharmacies
          • 5.3.1.2.2.3. E-Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Alzheimer's Therapeutics Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Alzheimer's Therapeutics Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Alzheimer's Therapeutics Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Alzheimer's Therapeutics Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Value Chain Analysis

11. Porter's Five Forces Analysis

12. PESTLE Analysis

13. Pricing Analysis

14. Market Dynamics

  • 14.1. Market Drivers
  • 14.2. Market Challenges

15. Market Trends and Developments

16. Regulatory Framework and Innovation

  • 16.1. Clinical Trials
  • 16.2. Regulatory Approvals

17. Patent Landscape

18. Case Studies

19. Competitive Landscape

  • 19.1. Competition Matrix of Top 5 Market Leaders
  • 19.2. SWOT Analysis for Top 5 Players
  • 19.3. Key Players Landscape for Top 10 Market Players
    • 19.3.1. AbbVie Inc.
      • 19.3.1.1. Company Details
      • 19.3.1.2. Key Management Personnel
      • 19.3.1.3. Products and Services
      • 19.3.1.4. Financials (As Reported)
      • 19.3.1.5. Key Market Focus and Geographical Presence
      • 19.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 19.3.2. Novartis AG
    • 19.3.3. Eisai Co., Ltd.
    • 19.3.4. Eli Lilly and Company
    • 19.3.5. Janssen Pharmaceuticals, Inc.
    • 19.3.6. F. Hoffmann La Roche Ltd.
    • 19.3.7. Daiichi Sankyo Company, Limited
    • 19.3.8. Bristol-Myers Squibb Company
    • 19.3.9. Teva Pharmaceuticals Ltd.
    • 19.3.10. Aurobindo Pharma Ltd.
    • 19.3.11. Biogen, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

20. Strategic Recommendations

21. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 3. Global Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 4. Global Alzheimer's Therapeutics Market Share (%), By Region, 2017-2031F
  • Figure 5. North America Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 6. North America Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 7. North America Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8. North America Alzheimer's Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 9. United States Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. United States Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 11. United States Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 12. Canada Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 13. Canada Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 14. Canada Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 15. Mexico Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Mexico Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 17. Mexico Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 18. Europe Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 19. Europe Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 20. Europe Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Europe Alzheimer's Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 22. Germany Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 23. Germany Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 24. Germany Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 25. France Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 26. France Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 27. France Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 28. Italy Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Italy Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 30. Italy Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 31. United Kingdom Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. United Kingdom Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 33. United Kingdom Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 34. Russia Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 35. Russia Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 36. Russia Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 37. Netherlands Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 38. Netherlands Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 39. Netherlands Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 40. Spain Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Spain Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 42. Spain Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 43. Turkey Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 44. Turkey Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 45. Turkey Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. Poland Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Poland Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 48. Poland Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 49. South America Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 50. South America Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 51. South America Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. South America Alzheimer's Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 53. Brazil Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. Brazil Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 55. Brazil Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 56. Argentina Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Argentina Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 58. Argentina Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59. Asia-Pacific Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 60. Asia-Pacific Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 61. Asia-Pacific Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 62. Asia-Pacific Alzheimer's Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 63. India Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 64. India Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 65. India Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 66. China Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 67. China Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 68. China Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 69. Japan Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Japan Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 71. Japan Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 72. Australia Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 73. Australia Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 74. Australia Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 75. Vietnam Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 76. Vietnam Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 77. Vietnam Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 78. South Korea Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 79. South Korea Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 80. South Korea Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 81. Indonesia Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Indonesia Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 83. Indonesia Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 84. Philippines Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 85. Philippines Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 86. Philippines Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 87. Middle East & Africa Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 88. Middle East & Africa Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 89. Middle East & Africa Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 90. Middle East & Africa Alzheimer's Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 91. Saudi Arabia Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 92. Saudi Arabia Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 93. Saudi Arabia Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. UAE Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. UAE Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 96. UAE Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 97. South Africa Alzheimer's Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 98. South Africa Alzheimer's Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 99. South Africa Alzheimer's Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 101. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 102. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023